CTOs on the Move

Frontage Laboratories

www.frontagelab.com

 
Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of molecules through development and file regulatory submissions in the United States, China and other countries.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Nanoscale Combinatorial Synthesis

Nanoscale Combinatorial Synthesis, Inc. is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southcoast Medical Group, P C

Southcoast Medical Group, P C is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Savannah, GA. To find more information about Southcoast Medical Group, P C, please visit www.southcoastmedical.com

CareQuest Inc

CareQuest Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Middle Tennessee Medical Center

Middle Tennessee Medical Center is a Murfreesboro, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.